BrainStorm advances ALS cell therapy with FDA-backed trial design
CGTLive - 10-Jul-2024New phase 3b study aims to resolve manufacturing challenges and support regulatory approval
Previously the Live Forever Club – now more focused on campaigning for radical life extension in the UK
Associate Editor at CGTLive
Victoria Johnson is a skilled and experienced healthcare journalist with a focus on biotech and pharma. She works as a freelance writer and editor, contributing to various publications and platforms in the life sciences sector. Her expertise includes reporting on clinical trials, regulatory issues, and the latest developments in drug development and innovation.
Victoria’s writing is well-regarded for its clarity and in-depth analysis, making complex scientific topics accessible to a broad audience. With a background in communications and a passion for healthcare, she plays a key role in bridging the gap between science and the public, offering valuable insights into the rapidly evolving field of biotechnology.
Visit website: https://www.cgtlive.com/authors/victoria-johnson
See alsoDetails last updated 18-Nov-2024
New phase 3b study aims to resolve manufacturing challenges and support regulatory approval
Multistem combats inflammation to improve trauma recovery